Embed this press release by copying the code below:
Pluristem's Phase I/II Muscle Injury Trial Successfully Meets Primary Safety & Efficacy Endpoints
Pluristem's Phase I/II Muscle Injury Trial Successfully Meets Primary Safety & Efficacy Endpoints